Alp Bio
2 known investors
Alp Bio operates a platform that combines human tonsil organoid technology with protein AI models to assess and reduce immunogenicity (anti-drug antibody) risk in therapeutic antibodies before clinical development. It serves biologics developers with in-silico ADA screening, ex vivo tonsil organoid assays, and generative redesign of antibody sequences.
Investors · 2
In the news
Frequently asked questions
- What does Alp Bio do?
- Alp Bio operates a platform that combines human tonsil organoid technology with protein AI models to assess and reduce immunogenicity (anti-drug antibody) risk in therapeutic antibodies before clinical development. It serves biologics developers with in-silico ADA screening, ex vivo tonsil organoid assays, and generative redesign of antibody sequences.
- Who are Alp Bio's investors?
- Alp Bio's investors include 42CAP, Venture Kick.